23 Feb Medtronic Pipeline Embolization Device Found Safe For Smaller Aneurysms
MedicalResearch.com Interview with:
Dr. Hanel
Ricardo A Hanel, MD PhD
Endovascular and Skull Base Neurosurgery
Director, Baptist Neurological Institute
Endowed Chair, Stroke and Cerebrovascular Surgery
Jacksonville, FL
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Medtronic Pipeline Embolization Device has been approved for carotid artery aneurysms over 10mm in size, from the petrous to clinoid segment but given the efficacy of results on these larger lesions, it has been widely utilized for treatment of smaller lesions. PREMIER came from the need of assessing the results , safety and efficacy, of pipeline for use of aneurysms under 12mm, located on the carotid artery, all segments, and V3 segment of the vertebral artery.
PREMIER enrolled 141 patients treated at 22 centers (21 US, 1 Canada). Primary Safety effectiveness defined as total aneurysm occlusion, core lab adjudicated , at 1 year was 83.5%; with safety endpoint of major stroke/death at 30 days of 1.4% (2 patients), with 1-year major stroke and death rate of 2.1%.
MedicalResearch.com: What should readers take away from your report?
Response: Pipeline embolization device is very effective and safe way to treat aneurysms under 12mm on the carotid artery and proximal vertebral artery, making Pipeline a well studied alternative for patients harboring these lesions
MedicalResearch.com: What recommendations do you have for future research as a result of this study?
Response: Further analysis of this data set should provide a better insight on which aneurysms are better suited for pipeline treatment.
Disclosures: Consultant: Medtronic, Stryker, COdman, Microvention; StockHolder : InNeuroCo. ressearch Grant: Microvention.
MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.
Citation: International Stroke Conference 2017
Prospective, Multi-Center Study of Flow Diversion for Small and Medium-Sized Aneurysms: Results of the Premier Trial LB3
Ricardo A Hanel, Baptist Neurological Inst, Jacksonville, FL
David Kallmes, Mayo Clinic, Rochester, MN
Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions
.
More Medical Research Interviews on MedicalResearch.com
Last Updated on February 23, 2017 by Marie Benz MD FAAD